Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Investors Discuss Funding Options In Difficult Market

May 11, 2005

By Jennifer Boggs

By Advancing GSK Agreement, Exelixis Gets $35M In Milestones

May 10, 2005

By Jennifer Boggs

By Advancing GSK Agreement, Exelixis Gets $35M In Milestones

May 10, 2005

By Jennifer Boggs

Erimos Builds Pipeline With Products For CIN, Tumors

May 9, 2005

By Jennifer Boggs

VioQuest Gets Cancer Products Through Greenwich Merger

May 9, 2005

By Jennifer Boggs

Erimos Builds Pipeline With Products For CIN, Tumors

May 9, 2005

By Jennifer Boggs

VioQuest Gets Cancer Products Through Greenwich Merger

May 9, 2005

By Jennifer Boggs

Bayhill Therapeutics Raises $35M In Series B For Autoimmune Drugs

May 6, 2005

By Jennifer Boggs

Bayhill Therapeutics Raises $35M In Series B For Autoimmune Drugs

May 6, 2005

By Jennifer Boggs

Cerovive Hits Primary Endpoint In Stroke Study; Renovis Soars

May 5, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...